ClinicalTrials.gg
CompletedNCT00174629Updated Dec 7, 2009

GILT Docetaxel - Non-Small Cell Lung Cancer

A Phase 3 interventional study of Docetaxel/DDP and docetaxel/gemcitabine in Lung Neoplasms, sponsored by Sanofi. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-07.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
449
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 23 studies in Lung Neoplasms by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Lung Neoplasms · Sanofi.

Enrollment
5th of 20
449 · median 132
Started
2001
with 1 other
Phase 3
7 of 23
none open now
Registered
3rd of 23
by date

Among the 23 studies in Lung Neoplasms by Sanofi, this one is the 5th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2001, is one of 7 in phase 3, and was the 3rd registered.

Lung Neoplasms

5,432 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

1 of the 23 studies in Lung Neoplasms by Sanofi is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 996 Lung Neoplasms studies recruiting now, 685 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Lung Neoplasms by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

  • To compare response rate between genotypic groups and control group.

Secondary Objective:

  • To determine the safety, time to treatment failure and survival in control and genotypic arms.
03

Conditions studied

  • Lung Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must be/have:

  • confirmed non-small cell lung cancer (squamous cell carcinoma, large cells or adenocarcinoma; it is recommended to provide the full paraffin-embedded block or at least 5 5 sections obtained from the primary tumor, recurrence or , not stained, fixed in formalin/embedded in paraffin, mounted on slides (10 micron sections), as well as two serum samples in two 10-ml tubes and two blood samples (see appendix X);
  • unresectable metastatic (stage IV or IIIB malignant pleural effusion) NSCLC;
  • \< 2;
  • Adequate bone marrow, hepatic and renal functions, assessed during the previous 14 days, that should be shown by the following characteristics:

    • > or = 10g/dl and no blood cell transfusion within the previous 2 weeks;
    • > 2.0 10\^9 cells/l;
    • count > or = 100.10\^9 cells/l;
    • no evidence of myelodysplastic syndrome or abnormal bone marrow reserve;
    • creatinine \< or = 1.5 x UNL or > or = 60 ml/min (real or calculated);
    • total \< or = UNL;
    • ASAT () and/or ALAT (SGPT) \< or = 1.5 x UNL;
    • alkaline phosphatases \< or = 5 x UNL;
    • serum calcium \< or = 1.1 x UNL;
  • at least one ;
  • previous surgery intervention (more than 30 days before inclusion in the study) is allowed but metastatic disease must be demonstrated;
  • previous radiotherapy is allowed if:

    • less or equal to 10% of bone marrow has been irradiated
    • end of radiotherapy 21 days or more prior to inclusion in the study;
    • patient has fully recovered from all toxic effects;
    • at least one of the measurable target lesions for evaluation of tumor response has not been irradiated;
  • the patient must be accessible for treatment and follow-up. The patient entered into this trial must be treated and followed up at the participating center;
  • > or = 12 weeks;
  • The initial diagnostic procedures should be performed during the 4 weeks prior to the randomization.

Exclusion criteria

Exclusion Criteria:

  • pregnant or lactating women (women of must use adequate );
  • prior systemic chemotherapy or immunotherapy for NSCLC, even as or adjuvant therapy;
  • prior , except cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix or other cancer curatively treated and with non-evidence of disease for at least 5 years;
  • history or clinical symptomatic brain or ;
  • current peripheral neuropathy and neurohearing > or = NCIC-CTG grade 2 except if due to trauma;
  • other serious illness or medical condition, including:

    • congestive heart disease; prior myocardial infarction within 6 months;
    • history of significant neurologic or psychiatric disorders that would inhibit their understanding and giving of ;
    • infection requiring I.V. antibiotics and tuberculosis under treatment ongoing at study entry;
    • untreated superior vena cava syndrome;
    • active peptic ulcer; unstable diabetes mellitus or other to high dose corticotherapy such as herpes, herpes zoster, cirrhosis;
  • hypercalcemia requiring therapy;
  • preexisting ascitis and/or clinical significant pericardial effusion;
  • patients whose lesion(s) are assessable only by radionuclide scan;
  • history of allergy to drugs containing the TWEEN 80®;
  • concurrent treatment with other drugs;
  • participation in a clinical trial of one or more investigational agents (i.e. antibiotic) or devices within 30 days of study entry.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
449 participants (actual)

Study arms

  • Experimental
    1

    Drug: docetaxel/gemcitabine

  • Active comparator
    2

    Drug: Docetaxel/DDP

Interventions

06

What researchers measure

Primary outcomes

  1. Overall response rate (complete plus partial responses) between the genotypic group and the control group using an intent-to-treat analysis.

Secondary outcomes

  1. Time to treatment failure and survival

    Time frame: calculated from the registration date until progression or death, respectively

  2. Clinical and laboratory toxicities graded according to NCIC-CTG Expanded Common Toxicity Criteria.

    Time frame: before each cycle

  3. Adverse events not reported in NCIC-CTG Expanded Common Toxicity Criteria will be graded as mild, moderate, severe, and life threatening.

    Time frame: Throughout the study

07

Study locations

3 sites
  • Sanofi-Aventis
    Berlin, Germany
  • Sanofi-Aventis
    Barcelona, Spain
  • Sanofi-Aventis
    Genève, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2001 and a primary completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Jun 2001
Primary completionActual
Jan 2007
Last update
Dec 7, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00174629
Lead sponsor
Sanofi
First posted
Sep 15, 2005
Start date
Jun 2001
Primary completion
Jan 2007
Last update
Dec 7, 2009

Study contacts

Jean-Philippe Aussel
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion